Marc Carrier: Important New Data From the API-CAT Trial on Recurrent VTE During Extended Apixaban Therapy
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on LinkedIn about a recent article by Isabelle Mahé et al, published in Circulation, adding:
”Exciting results presented by Prof Isabelle Mahé at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, with simultaneous publication in Circulation.
Key findings from this pre-specified ancillary analysis of the API-CAT trial include:
- Recurrent VTE during extended apixaban therapy was uncommon, occurring in only 2.5% of 1,766 patients over 12 months.
- The risk of recurrence differed by cancer type, with the highest incidence observed in gastrointestinal cancers (excluding colorectal).
- The index VTE strongly predicted the pattern of recurrence. Patients presenting initially with PE were most likely to recur with PE, while those with isolated DVT recurred exclusively with DVT.
- Despite its low frequency, recurrent VTE carried a very poor short-term prognosis, with 50% mortality occurring within a median of just 24 days following recurrence.”
Title: Prognosis of Recurrent Venous Thromboembolism During Extended Apixaban Therapy for Cancer-Associated Thrombosis: Insights From the API-CAT Randomized Trial
Authors: Isabelle Mahé, Céline Chapelle, Marc Righini, Grégoire Le Gal, Frederikus A. Klok, Giancarlo Agnelli, Francis Cajfinger, Marie-Antoinette Sevestre, Philippe A. Grenier, Jérôme Alexandre, Francis Couturaud, Patrick Mismetti, Silvy Laporte, Jean Chidiac

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering
-
Aug 13, 2026, 16:07Jackie Kunzler: Accelerating Innovation in Blood Processing
-
Aug 13, 2026, 16:02Pablo Corral: Is Inflammation Really a Therapeutic Target in Atherosclerosis
-
Aug 13, 2026, 15:47Breck Gamel: Why Factor V Leiden Matters
-
Aug 13, 2026, 15:25Douglas Tavares: Clinical Strategies to Reduce Blood Transfusion and Donor Reliance
-
Aug 13, 2026, 15:21Naghmeh N.: Freeze Dried Plasma Could Transform Emergency Trauma Care